Sandro Marini^1,2*, Michelle Kaku¹, Stephanie L Bissonnette¹ and Ornella Dubaz²

¹Department of Neurology, Boston University Medical Center, Boston, MA, USA
²Neurology Service, Department of Veterans Affairs (VA) Medical Center, Boston, MA, USA

*Corresponding Author: Sandro Marini, Department of Neurology, Boston University Medical Center, Boston, MA, USA.

Received: August 02, 2021; Published: August 13, 2021

Abstract

Huntington’s disease (HD) and multiple sclerosis (MS) are two neurodegenerative diseases for which different pathologies and limited commonalities have been described. Here, we report the second case in the literature of comorbid MS and HD. When comorbidity occurs between rare diseases, shared pathological pathways may be suspected and common genetic or environmental triggers can be hypothesized to ultimately advance the understanding of the two diseases.

Keywords: Multiple Sclerosis; Huntington’s Disease; Commonalities; Toxin Exposure; Case Report

References

1. Chaganti SS., et al. “What do we know about Late Onset Huntington’s Disease?” Journal of Huntington's Disease 2 (2017): 95-103.
2. Axisa PP and Hafler DA. “Multiple sclerosis: Genetics, biomarkers, treatments”. Current Opinion in Neurology3 (2016): 345-353.
3. Maloni HW and Wallin MT. “Presentation of multiple sclerosis with comorbid Huntington’s disease”. Clinical Neurology and Neurosurgery 136 (2015): 86-88.
4. Murphy R., et al. “Neuropsychiatric syndromes of multiple sclerosis”. Journal of Neurology, Neurosurgery and Psychiatry8 (2017): 697-708.
5. Snowden JS. “The Neuropsychology of Huntington’s Disease”. Archives of Clinical Neuropsychology7 (2017): 876-887.
6. Steenhof M., et al. “Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases”. Multiple Sclerosis and Related Disorders 32 (2019): 97-102.
7. Beecham AH., et al. “Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis”. Nature Genetics 45 (2013): 1353-1360.
8. Barragán-Martínez C., et al. “Organic Solvents as Risk Factor for Autoimmune Diseases: A Systematic Review and Meta-Analysis”. PLoS One12 (2012): e51506.
9. Gusella JF., et al. “Genetic modifiers of Huntington’s disease”. Movement Disorders 11 (2014): 1359-1365.
10. Thomson SB and Leavitt BR. “Transcriptional regulation of the huntingtin gene”. Journal of Huntington's Disease4 (2018): 289-296.

Citation

Citation: Sandro Marini., et al. “Comorbid Multiple Sclerosis and Huntington’s Disease". Acta Scientific Neurology 4.9 (2021): 34-36.

Copyright

Copyright: © 2021 Sandro Marini., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.